Patients with a recent history of myocardial infarction or whose condition might be exacerbated by an increase in heart rate. Due to the risk of dose-related increases in blood pressure, blood pressure measurement should be performed regularly during therapy.
Measurement of serum-cholesterol levels should also be considered with long-term treatment.
Venlafaxine should be used with caution in patients with moderate to severe hepatic or renal impairment and dosage adjustment may be necessary.
It should also be used with caution in patients with a history of epilepsy and avoided in those with unstable disease; it should be stopped in any patient developing a seizure or if there is an increase in seizure frequency.
Caution is also advised in patients with a history of bleeding disorders or of hypomania or mania.
Patients with raised intra-ocular pressure or at risk of angle-closure glaucoma should be monitored closely.
Patients who develop a rash, urticaria, or related allergic reaction with venlafaxine should be advised to contact their doctor.
Patients, especially the elderly, should be warned of the risk of dizziness or unsteadiness due to orthostatic hypotension.
Symptoms reported on abrupt withdrawal or dose reduction of venlafaxine include fatigue, somnolence, headache, nausea, vomiting, anorexia, palpitations, dizziness, dry mouth, diarrhoea, insomnia, agitation, anxiety, nervousness, confusion, hypomania, paraesthesia, sweating, and vertigo.
Capsule: Venlafaxine STADA 37.5 mg contains lactose and therefore this medicine should not be taken by patients with rare hereditary problems of galactose intolerance, total lactase deficiency or Glucose-galactose malabsorption should not take this medicine.
Effects on ability to drive and use machines: As with other antidepressants, venlafaxine may impair performance of skilled tasks and, if affected, patients should not drive or operate machinery.